“You really believe that? You think it’s all on NP?
Yes, I believe NP shoulders most of the blame for shortcomings with HIV and cancer (and some with COVID). I’ve never bought into the Big Pharma (BP) conspiracies and to somehow blame BP more than NP, without any evidence, is hard for me to do. NP is a salesman and has always managed CYDY with the hope that leronlimab would hit a home run, be bought out buy BP, and NP would retire a millionaire. He’s always tried to spend as little as possible while attempting to achieve the near impossible, which has so far not panned out. Not having a legitimate researcher/scientist is what caused the issues with the HIV BLA, not the FDA. Can you imagine NP trying to discuss trial protocol or results with the FDA? He obviously had help, but not the help CYDY needed and that was due to him trying to keep costs low (while also overpaying himself). And then when he did hire someone, he hires Scott Kelly, a PM&R doctor who spent most of his time developing orthopedic centers. Basically he brought in another businessman with no real FDA or clinical trial experience (yes, CYDY is pre-revenue biotech).
Now, has he done good things? Of course. He pushed leronlimab for monotherapy which I still think is a game changing indication (if it ever completed a phase 3 before competition comes along). He connected with Dr. Pestell and Dr. Patterson to bring in cancer and COVID (no, Pestell didn’t pan out). He pushed for EINDs for COVID, demonstrating MOA and leading to trials. More recently, he increased enrollment in the S/C trial by a multiple of 2-3.
Long story short, it’s hard for me to see others deeply blame BP without evidence and without acknowledging the major shortcomings surrounding NP. Regardless, this will all be forgotten (at least for a few months!) if leronlimab is approved for COVID.
Yes, I believe NP shoulders most of the blame for shortcomings with HIV and cancer (and some with COVID). I’ve never bought into the Big Pharma (BP) conspiracies and to somehow blame BP more than NP, without any evidence, is hard for me to do. NP is a salesman and has always managed CYDY with the hope that leronlimab would hit a home run, be bought out buy BP, and NP would retire a millionaire. He’s always tried to spend as little as possible while attempting to achieve the near impossible, which has so far not panned out. Not having a legitimate researcher/scientist is what caused the issues with the HIV BLA, not the FDA. Can you imagine NP trying to discuss trial protocol or results with the FDA? He obviously had help, but not the help CYDY needed and that was due to him trying to keep costs low (while also overpaying himself). And then when he did hire someone, he hires Scott Kelly, a PM&R doctor who spent most of his time developing orthopedic centers. Basically he brought in another businessman with no real FDA or clinical trial experience (yes, CYDY is pre-revenue biotech).
Now, has he done good things? Of course. He pushed leronlimab for monotherapy which I still think is a game changing indication (if it ever completed a phase 3 before competition comes along). He connected with Dr. Pestell and Dr. Patterson to bring in cancer and COVID (no, Pestell didn’t pan out). He pushed for EINDs for COVID, demonstrating MOA and leading to trials. More recently, he increased enrollment in the S/C trial by a multiple of 2-3.
Long story short, it’s hard for me to see others deeply blame BP without evidence and without acknowledging the major shortcomings surrounding NP. Regardless, this will all be forgotten (at least for a few months!) if leronlimab is approved for COVID.
6
1
